Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura Academic Article Article uri icon

Overview

MeSH Major

  • Asthma
  • Bronchoalveolar Lavage Fluid
  • Glycoproteins

abstract

  • In this small, randomized trial, low-dose IVIG in 2-day regimens of 250, 400, or 500 mg/kg/day rapidly reversed thrombocytopenia just as effectively as 1 g/kg/day in infants and young children with ITP. Lower-dosage regimens are safe and well-tolerated; the incidence of AEs is lower in children younger than 5 years of age.

publication date

  • May 1997

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1097/00043426-199705000-00004

PubMed ID

  • 9201140

Additional Document Info

start page

  • 197

end page

  • 201

volume

  • 19

number

  • 3